Cosmegen VL 0.5mg ASD(Dactinomycin)

Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Cosmegen VL
Manufacturer	ASD/RECORDATI
Prescription required	Yes

Description

Cosmegen VL 0.5mg ASD(Dactinomycin) is a medicine catalog record in the MediPriceHub database. Active ingredient: DACTINOMYCIN. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: ASD/RECORDATI. Therapeutic category: Medicine Library > Oncology Medicines > Testicular Cancer Medicines. Pack information: 0.5 / 1. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

Dactinomycin for Injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion. 1.1 Wilms Tumor Dactinomycin for Injection is indicated for the treatment of adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. 1.2 Rhabdomyosarcoma Dactinomycin for Injection is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. 1.3 Ewing Sarcoma Dactinomycin for Injection is indicated for the treatment of adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. 1.4 Metastatic Nonseminomatous Testicular Cancer Dactinomycin for Injection is indicated for the treatment of adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. 1.5 Gestational Trophoblastic Neoplasia Dactinomycin for Injection is indicated for the treatment of post-menarchal patients with gestational trophoblastic neoplasia,

How to Use

Use DACTINOMYCIN under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: DACTINOMYCIN. Pack size: 0.5 / 1. Pack unit: bottle. Manufacturer: ASD/RECORDATI. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Testicular Cancer Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

Esta información es solo orientativa. Consulta a un profesional sanitario antes de usar cualquier medicamento.